Travere Therapeutics, Inc. TVTX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s total liabilities?
- Travere Therapeutics, Inc. (TVTX) reported total liabilities of $456.46M in Q1 2026.
- How has Travere Therapeutics, Inc.'s total liabilities changed year-over-year?
- Travere Therapeutics, Inc.'s total liabilities decreased by 11.5% year-over-year, from $515.98M to $456.46M.
- What is the long-term trend for Travere Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s total liabilities has grown at a 49.8% compound annual growth rate (CAGR), from $65.1M to $490.36M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.